news
Grapheton Inc. Appoints New CEO. San Diego, California–(PRNewswire – October 13, 2021) – Grapheton, Inc., a pioneer in carbon-based biocompatible probes and power sources for brain-computer interfaces (BCI), today announced that Terry Lingren has been appointed Chief Executive Officer.
Mr. Lingren joins Grapheton with a proven track record of leadership in growing technology startups from concept through market entry and high-volume manufacturing. He was the founding CEO of Resonant Inc. in 2012 and led it through its initial public offering in 2014 before retiring in 2017. Prior to Resonant, Mr. Lingren held executive and engineering positions at Qualcomm Inc. and Kyocera Wireless Corporation that led from the initial cellphone concept into dozens of products shipping millions of units per year.
“Terry’s experience in growing highly technical startups with novel products into revenue-producing companies is exactly the emphasis we need at this juncture in Grapheton’s young life,” said Sam Kassegne, Grapheton’s Co-Founder and Chairman of the Board. “His expertise and impressive track record in nurturing companies from early concepts into high-volume products will be invaluable as we move forward with commercialization of our BCI products.”
Mr. Lingren added, “I am excited to be joining Sam and his team on what I believe are disruptive products in the BCI market. This industry is poised for growth in helping people overcome disabilities and enhance their innate capabilities, and I hope to position Grapheton firmly in this growth.” More here.
US Nuclear (OTC: UCLE) recently entered into a stock purchase agreement with start-up Grapheton Inc. to acquire a 40% stake in the company. According to the update, Grapheton, similar to Elon Musk’s “Neuralink,” is developing and manufacturing an advanced new generation of wearable and implantable brain-machine interface devices. Grapheton already has several pivotal and patented advantages in the field with products already in use at various research centers. The company’s long-term goal is dedicated specifically to treating injuries and disease such as spinal injuries, pain reduction, Parkinson’s Disease, epilepsy, stroke, and possibly Alzheimer’s.
Grapheton’s products are already in use at various research centers and currently include: ECoG probes (electrocorticography- monitoring the electrical activity of the brain), spinal stimulation probes for spinal injuries, brain chemical sensors, surface electrodes for MRIs, and other micro-electrode arrays and electrochemical sensors. US Nuclear will provide systems engineering, manufacturing, and marketing support to help Grapheton leverage their unique patented advantages and make these products commercially available to all people who can benefit from them. US Nuclear’s monetary support will also enable Grapheton to research and develop new and exciting brain-machine interface products.